

Chiesi Group 2019 Aggregated Scoring Methodology Summary

Aggregated Scoring Methodology

Chiesi Farmaceutici S.p.A and all of its subsidiaries were required to be assessed in the B Impact Assessment and undergo a review by B Lab staff. Chiesi Farmaceutici Spa and its subsidiaries were divided into 18 assessments, and the overall score was calculated using a employee-based weighted average. The 18 assessments are as follows:

- Chiesi Farmaceutici S.p.A (IT)¹
- Chiesi Pharmaceuticals GmbH (AT)²
- Chiesi GmbH (DE)
- Chiesi Poland SP. Z.o.o (PL)
- Chiesi S.A.S. (FR)
- Chiesi Pharma AB (SE)³
- LLC Chiesi Pharmaceuticals (RU)
- Chiesi S.A. (BE)
- Chiesi Farmaceutica LTDA. (BR)
- Chiesi Espana S.A.U. (ES)
- Chiesi USA Inc. (US)⁴
- Chiesi Pharmaceuticals BV (NL)
- Chiesi Pharmaceuticals Shanghai Co. Ltd. (CN)
- Chiesi Hellas Pharmaceuticals S.A. (GR)
- Chiesi Pharmaceuticals PVT. Limited (PK)⁵
- Chiesi Ilac Ticaret A.S. (TR)⁶
- Chiesi Healthcare Limited (GB)⁷

The Group scored an overall 87.5 out of 200 total available points. The minimum verified score required for B Corp Certification is 80.

Learn more about the [B Impact Assessment](#).

¹ Assessment for Chiesi Farmaceutici S.p.A (IT) includes Marco Antonetto (IT), Atopix Therapeutics Limited (GB), Chiesi Orphan GmbH (DE), Chiesi S.A. (CH) and Daroo Gostaran Khavare Mianeh (IR)

² Assessment for Chiesi Pharmaceuticals GmbH includes Chiesi Romania S.r.l. (RO), Chiesi CZ S.r.o. (CZ), Chiesi Slovenija D.o.o. (SI), Chiesi Hungary Kft (HU), Chiesi Slovakia S.r.o. (SK), Chiesi Bulgaria Ltd. (BG)

³ Assessment for Chiesi Pharma AB (SE) includes Zymenex Holding A/S (DK), Ace Biosciences A/S (DK) and Zymenex A/S (DK) as entities will be merged in August 2018

⁴ Assessment for Chiesi USA Inc. (US) includes Cornerstone Biopharma Inc, EKR Holdings Inc, EKR Therapeutics LLC and Chiesi Pharmaceuticals (US)

⁵ Assessment for Chiesi Pharmaceuticals PVT. Limited (PK) includes Master Pharma Private Limited (PK)

⁶ Assessment for Chiesi Ilac Ticaret A.S. (TR) includes Promedia Ilac Ticaret L.S. (TR)

⁷ Assessment for Chiesi Healthcare Limited (GB) includes Chiesi Limited (GB) and Cheshire Healthcare Limited (GB)

Chiesi Group
2019 Aggregated Scoring Methodology Summary

Subsidiaries

As the B Corporation Certification is a company-level certification, the assessment of a Parent Company is required to include its subsidiaries in which it owns >50% of the shares and has controlling interest. Depending on the operations of the certifying company, Parent Companies may roll up their subsidiaries into a single assessment or assess separately.

Regardless of whether a Certified Parent Company's subsidiaries are assessed together or separately, only distinct subsidiaries that B Lab has determined independently meet the performance requirement for certification are eligible to use the Certified B Corporation logo and refer to themselves as Certified B Corporations.

The overall scores for individual company assessments, which were used by B Lab to determine the overall score of Chiesi Group, are listed below.

Company name	Overall BIA score
Chiesi Farmaceutici Spa	93.7
Chiesi Limited	87.3
Chiesi Pharmaceutica Shanghai Co.Ltd	86.6
Chiesi USA Inc	87.3
Chiesi GmbH	87.2
Chiesi Farmaceutica Ltda	91.9
Chiesi Pharmaceuticals B.V.	88.3
Chiesi Pharmaceuticals GmbH	83.0
Chiesi Espana S.A.U.	75.7
Chiesi Pakistan	86.8
Chiesi S.A.	78.8
Chiesi Pharma AB	90.8
Chiesi E/ΛΛΣ AEBE	82.9
Chiesi İlaç Ticaret A.Ş	75.8
Chiesi Poland	86.0
OOO Chiesi Pharmaceuticals	73.5
Chiesi SA/NV	73.4
Chiesi Mexico	79.7